Exercise program for breast cancer patients
Breast Cancer Exercise Intervention Study (BREXINT)
This study tests whether a 24-week exercise program can improve fitness, strength, and quality of life for breast cancer patients who have finished their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2156 (estimated) |
| Ages | 21 Years to 99 Years |
| Sex | Female |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Singapore and 2 other locations) |
| Trial ID | NCT05957068 on ClinicalTrials.gov |
What this trial studies
This clinical trial involves a 24-week exercise program designed for patients with early-stage and locally advanced breast cancer who have undergone curative surgery and completed chemotherapy or radiotherapy. The program includes aerobic exercise and muscle strength training, with the first nine sessions supervised in person by physiotherapists, followed by remote monitoring or supervision at local gyms. The study aims to assess the impact of this exercise intervention on cardiorespiratory fitness, muscle strength, and quality of life among participants. Blood samples and questionnaires will be collected periodically to evaluate health outcomes.
Who should consider this trial
Good fit: Ideal candidates are females aged 21 and older with stage 1, 2, or 3 breast cancer who have recently undergone curative surgery and completed any necessary adjuvant treatments.
Not a fit: Patients with significant cardiovascular, respiratory, or musculoskeletal issues that prevent moderate physical activity may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could enhance physical fitness and quality of life for breast cancer survivors.
How similar studies have performed: Other studies have shown positive outcomes with exercise interventions for cancer patients, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically or cytologically proven stage 1, 2, or 3 breast cancer * Patients who have undergone curative breast surgery * Patients who have received (neo)adjuvant chemotherapy (if given) and/or radiotherapy (if given) * Females aged 21 years and older * ≤ 8 weeks from breast surgery, or the last adjuvant chemotherapy or radiotherapy session, whichever is latest. Exclusion Criteria: * Cardiovascular, respiratory, musculoskeletal problems that preclude moderate physical activity. * Major medical problems that are deemed by the investigator to be unsuitable for enrollment.
Where this trial is running
Singapore and 2 other locations
- National University Hospital — Singapore, Singapore (Recruiting)
- National Cancer Centre — Singapore, Singapore (Recruiting)
- Singapore General Hospital — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Dr Elaine LIM, MD, PhD — National Cancer Centre, Singapore
- Study coordinator: Dr Elaine LIM, MD, PhD
- Email: elaine.lim.hsuen@singhealth.com.sg
- Phone: +65 64368000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.